Hypoplastic left heart syndrome: from comfort care to long-term survival

Mouhammad Yabrodi1, Christopher W Mastropietro1

  • 1Department of Pediatrics, Section of Critical Care, Riley Hospital for Children at Indiana University Health and Indiana University School of Medicine, Indianapolis, Indiana.

Pediatric Research
|October 5, 2016
PubMed

Insights

Hypoplastic left heart syndrome (HLHS) management evolved from supportive care to surgical interventions like the Norwood procedure. These advancements significantly improve survival rates for affected children.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease Surgery
  • Neonatal Intensive Care

Background:

  • Hypoplastic Left Heart Syndrome (HLHS) historically had a poor prognosis, with most infants succumbing to the condition in the neonatal period.
  • Early management in the 1970s was limited to supportive care, offering little hope for long-term survival.
  • The lack of effective treatments necessitated a paradigm shift in pediatric cardiac care.

Observation:

  • The introduction of the Norwood procedure in the early 1980s marked a turning point in HLHS management.
  • This surgical innovation initiated a series of palliative procedures aimed at supporting single-ventricle physiology.
  • Subsequent decades have seen continuous refinement of surgical techniques and perioperative care.

Findings:

  • Modern HLHS management, centered around staged surgical palliation including the Norwood procedure, enables survival beyond infancy.
  • A majority of children with HLHS now survive the neonatal period and can live into early adulthood.
  • Innovations over the past 40 years have dramatically altered the clinical course and outcomes for HLHS patients.

Implications:

  • The advancements in HLHS treatment offer improved quality of life and extended survival for affected individuals.
  • Continued research into surgical techniques and long-term care is crucial for further enhancing outcomes.
  • The evolution of HLHS management serves as a model for progress in treating complex congenital heart defects.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
574
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
702
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
413
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
497
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
434